Navigation Links
For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain

WALTHAM, Mass., Dec. 7 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite its dominance in early lines of metastatic colorectal cancer treatment, Roche/Chugai's Avastin will face increasing competition from Bristol-Myers Squibb/Eli Lilly/Merck KGaA's Erbitux in Germany, France and Spain.

The new Special European Physician & Payer Forum report entitled Metastatic Colorectal Cancer in Europe: Changing Dynamics in Light of Increasing Segmentation and New Therapeutic Options finds that more than half of surveyed oncologists in Germany, France and Spain indicate that the existence of a validated biomarker for Erbitux has decreased their prescribing of Avastin in a subpopulation of patients with metastatic colorectal cancer. Sales of Erbitux in these countries will be driven by its use to treat patients with wild-type KRAS (Kirsten rat sarcoma 2 viral oncogene) metastatic colorectal cancer. However, the existence of a validated biomarker for Erbitux has not had a significant impact on the prescribing of Avastin in Italy, which is likely due to the currently low levels of KRAS testing in this country.

"More than half of oncologists in France and Italy say they use Avastin-containing regimens as first-line treatment in patients known to have wild-type KRAS metastatic colorectal cancer, despite a valid biomarker proving the efficacy of Erbitux in this population," said Decision Resources Analyst Marcus Hoyle, B.Sc. "However, in Spain, the majority of oncologists say they use Erbitux-containing regimens in this setting, which is most likely due to the high levels of KRAS testing in Spain as compared to other countries."

The report finds that reimbursement of KRAS testing varies between the European countries surveyed. In France and Spain, KRAS testing is reimbursed but in Germany KRAS testing is not covered by all health insurance systems. As a result, the proportion of patients tested for KRAS status in Germany is substantially lower than the proportion tested in France and Spain. The proportion of patients tested for KRAS status in the United Kingdom, which is currently low, will increase significantly over the next 12 months.

Metastatic Colorectal Cancer in Europe: Changing Dynamics in Light of Increasing Segmentation and New Therapeutic Options is based on surveys with 224 oncologists and interviews with 20 hospital-based payers in Germany, France, Italy, Spain and the United Kingdom. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources                        Decision Resources, Inc.
Christopher Comfort                       Elizabeth Marshall
781-296-2597                              781-296-2563         

SOURCE Decision Resources

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Post Your Comments:
(Date:11/24/2015)... , November 24, 2015 Sectra ... Acadiana has entered into a multi-year agreement to ... centers. This investment will provide the Breast Center a ... Sectra (STO: SECT B) announces that Breast ... agreement to deploy Breast Imaging PACS in its two ...
(Date:11/24/2015)... 2015   HeartWare International, Inc . (NASDAQ: ... support technologies that are revolutionizing the treatment of advanced ... Officer Doug Godshall is scheduled to present ... Conference on December 1, 2015 at 3:00 p.m. ET.  ... New York . ...
(Date:11/24/2015)... and BERN, Switzerland , ... the ARTORG Center for Biomedical Engineering Research of the ... the Division of Endocrinology, Diabetes and Clinical Nutrition of ... the start of an exclusive collaboration to develop a ... algorithm for the personalised delivery of insulin for diabetic ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 25, 2015 , ... Many people know ... fuzzy-headedness, weight gain, cold hands, and dry skin. But many people who find their ... and exercise regimen instead of their thyroid, especially if they don’t have any of ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since ... providing comprehensive solutions involving adult stem cell therapies to patients with chronic degenerative ... “Regenestem” name as a Registered Trademark (RTM). , Organizations are required to hold ...
(Date:11/25/2015)... ... 25, 2015 , ... Bunion Bootie , the newest ... of the early holiday shopping season. Starting Wednesday November 25th, Bunion Booties are ... Friday promotional pricing is in addition to any automatic discounts applied when buying ...
(Date:11/24/2015)... PA (PRWEB) , ... November 24, 2015 , ... ... now certified to offer their patients the many benefits of the revolutionary BIOLASE ... the sharp cutting and scraping tools traditionally used by a dentist in ...
(Date:11/24/2015)... ... ... New patients who wish to seek treatment for missing teeth can now ... Mississauga, ON practice. Dr. Williams has been providing dental service for over 34 years, ... teeth can lead to a variety of complications if they are not replaced quickly, ...
Breaking Medicine News(10 mins):